Menu
Immunotherapy for solid tumors, especially “immunologically cold tumors” like breast and prostate cancer, has often failed due to the complex immunosuppressive tumor microenvironment neutralizing an antitumor immune response. Our therapeutic not only recruits potent anti-tumor immune cells, but also inhibits multiple key immunosuppressive factors in the tumor microenvironment. Our technology even has the potential to improve efficacy of prior promising therapies that have failed in the clinic.
After surgical removal, patients who have recurrence of their prostate or breast cancers receive hormone ablation therapy (castration) to inhibit the cancer-causing transcription factors and slow growth. However, the transcription factors undergo resistance mechanisms within 1-2 years and continue driving cancer growth. As our therapeutic is driven by the cancer-causing transcription factors, it not only prevents resistance, but also allows patients to delay or avoid castration therapy.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
